Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Aadhar Housing Finance IPO Date, Review, Price, Allotment Details

By IPOWatch Team
May 9, 2024

Aadhar Housing Finance IPO Details: Aadhar Housing Finance IPO date is fixed, the IPO is to hit the market on May 8 and will close on May 10. Aadhar Housing Finance IPO to raise around ₹3000 crores via IPO that comprises fresh issue of ₹1000 crores and offer for sale up to 63,492,063 equity shares of ₹10 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.

Aadhar Housing Finance offers a range of mortgage-related loan products, including loans for residential property purchase and construction; home improvement and extension loans; and loans for commercial property construction and acquisition. Their financial performance has remained consistent and resilient through various external events in the Indian economy.

They have made social objectives one of the core objectives of their business model. They operate a financially inclusive, customer-centric lending business and believe that their business model contributes significantly to the economic uplift of their target customers by contributing to an improvement in their standard of living. In addition to their customer-facing social objectives, they have also implemented social objectives in aspects of their business. Their presence in urban and semi-urban locations across India provides a source of employment in these locations.

They have an extensive network of 471 branches* including 91 sales offices, as of September 30, 2023. Their branches and sales offices are spread across 20 states and union territories, operating in approximately 10,926 pin codes across India, as of September 30, 2023.

Objects of the Issue

To meet future capital requirements towards onward lending
General corporate purposes.

Aadhar Housing Finance IPO Review (Apply or Not)

Apply

Brokerage Firm IPO Review

BP Equities (BP Wealth): Apply
Marwadi Shares and Finance: Apply
SMC Global: Neutral
Swastika Investmart: May Apply
Systematix Shares and Stocks: Apply

Aadhar Housing Finance IPO Date & Price Band Details

IPO Open:	May 8, 2024
IPO Close:	May 10, 2024
IPO Size:	Approx ₹3000 Crores
Fresh Issue:	Approx ₹1000 Crores
Offer for Sale:	Approx ₹2000 Crores
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹300 to ₹315 Per Share
IPO Listing on:	BSE & NSE
Retail Quota:	35%
QIB Quota:	50%
NII Quota:	15%
Discount:	N/A
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors List:	Click Here

Aadhar Housing Finance IPO Market Lot

The Aadhar Housing Finance IPO minimum market lot is 47 shares with ₹14,805application amount. The retail investors can apply up-to 13 lots with 611 shares or ₹192,465 amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	47	₹14,805
Retail Maximum	13	611	₹192,465
S-HNI Minimum	14	658	₹207,270
B-HNI Minimum	68	3196	₹1,006,740

Aadhar Housing Finance IPO Allotment & Listing Dates

The Aadhar Housing Finance IPO date is May 8 and the close date is May 10. The Aadhar Housing Finance IPO allotment will be finalized on May 13 and the IPO listing on May 15.

Price Band Announcement:	May 7, 2024
IPO Open Date:	May 8, 2024
IPO Close Date:	May 10, 2024
Basis of Allotment:	May 13, 2024
Refunds:	May 14, 2024
Credit to Demat Account:	May 14, 2024
IPO Listing Date:	May 15, 2024

You can check IPO subscription status and IPO allotment status on their respective pages.

Aadhar Housing Finance IPO Form

How to apply for the Aadhar Housing Finance IPO? You can apply for Aadhar Housing Finance IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Aadhar Housing Finance IPO in the Invest section. The other option is you can apply for Aadhar Housing Finance IPO via IPO forms downloaded via NSE and BSE. Check out the Aadhar Housing Finance forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.

Aadhar Housing Finance Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹1575.55	₹1143.04	₹340.13
2022	₹1728.56	₹1161.20	₹444.85
2023	₹2043.52	₹1322.70	₹544.76
Dec 2023	₹1895.17	₹1194.19	₹547.88

Aadhar Housing Finance IPO Valuation – FY2023

Check Aadhar Housing Finance IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹13.8 per Equity Share
Price/Earning P/E Ratio:	[.]
Return on Net Worth (RoNW):	14.7%
Net Asset Value (NAV):	₹93.7 per Equity Share

Peer Group

Aptus Value Housing Finance India Limited
Aavas Financiers Limited
Home First Finance Company India Limited
India Shelter Finance Corporation Limited

Company Promoters

BCP Topco VII Pte. Ltd

Aadhar Housing Finance IPO Registrar

KFin Technologies Pvt. Ltd
Phone: +91 40 6716 2222
Email: ahfl.ipo@kfintech.com
Website: www.kfintech.com

Aadhar Housing Finance IPO Allotment Status Check

Check Aadhar Housing Finance IPO allotment status on KFintech website allotment URL. Click Here

Aadhar Housing Finance IPO Lead Managers aka Merchant Bankers

ICICI Securities Limited
Citigroup Global Markets India Private Limited
Kotak Mahindra Capital Company Limited
Nomura Financial Advisory and Securities (India) Private Limited
SBI Capital Markets Limited

Company Address

Aadhar Housing Finance Limited
Unit No. 802, 8th Floor, Natraj by Rustomjee,
Junction of Western Express Highway and M. V. Road,
Andheri (East), Mumbai 400 069, Maharashtra
Phone: +91 22 3950 9900
Email: complianceofficer@aadharhousing.com
Website: www.aadharhousing.com

Aadhar Housing Finance IPO FAQs

What is Aadhar Housing Finance IPO?

Aadhar Housing Finance IPO is a main-board IPO. They are going to raise ₹3000 Crores via IPO. The issue is priced at ₹300 to ₹315 pr equity share. The IPO is to be listed on BSE & NSE.

When Aadhar Housing Finance IPO will open?

The IPO is to open on May 8, 2024 for QIB, NII, and Retail Investors.

What is Aadhar Housing Finance IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Aadhar Housing Finance IPO?

You can apply for Aadhar Housing Finance IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Aadhar Housing Finance IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Aadhar Housing Finance”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Aadhar Housing Finance IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Aadhar Housing Finance”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Aadhar Housing Finance IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Aadhar Housing Finance”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Aadhar Housing Finance IPO Size?

Aadhar Housing Finance IPO size is ₹3000 crores.

What is Aadhar Housing Finance IPO Price Band?

Aadhar Housing Finance IPO Price Band is ₹300 to ₹315.

What is Aadhar Housing Finance IPO Minimum and Maximum Lot Size?

The minimum bid is 47 Shares with ₹14,805 amount while the maximum bid is 13 shares with ₹192,465.

What is the Aadhar Housing Finance IPO Allotment Date?

Aadhar Housing Finance IPO allotment date is May 13, 2024.

What is the Aadhar Housing Finance IPO Listing Date?

Aadhar Housing Finance IPO listing date is May 15, 2024. The IPO is to list on BSE and NSE.

Note: The Aadhar Housing Finance IPO price band and date are not officially announced yet. The IPO grey market premium (Aadhar Housing Finance IPO Premium) will be added to the IPO grey market page as it will start).